Literature DB >> 35400120

Mediastinal and hilar sarcoid-like reaction in a patient treated with dabrafenib and trametinib for metastatic melanoma: A case report and review of the literature.

Vanessa-Meletia Bala1, Maria Mitsogianni1, Konstantinos Laschos1, Evangelia Pliakou1, Eirini Lazaridi1, Dimitra-Ioanna Lampropoulou1, Gerasimos Aravantinos1.   

Abstract

BRAF/MEK inhibitors are considered standard of care in the treatment of advanced BRAF-mutated malignant melanoma, and have been, in rare cases, associated with granulomatous reactions, mostly limited to skin lesions. The present study reported the case of a patient with metastatic melanoma developing a sarcoid-like reaction manifesting as asymptomatic mediastinal and right hilar lymphadenopathy while on antineoplastic therapy with dabrafenib and trametinib. To the best of our knowledge, this is the first reported case of isolated lymphadenopathy as a manifestation of drug-induced sarcoid-like reaction under dabrafenib and trametinib. Overall, only 17 other cases of granulomatosis have been reported in the literature. Although uncommon, such reactions should be considered in the differential diagnosis of lymph node enlargement, and distinguishing them from tumor progress is important and can be challenging in clinical practice.
Copyright © 2020, Spandidos Publications.

Entities:  

Keywords:  BRAF/MEK inhibitors; dabrafenib; melanoma; sarcoidosis; trametinib

Year:  2022        PMID: 35400120      PMCID: PMC8985069          DOI: 10.3892/mco.2022.2532

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  24 in total

1.  Acute heart failure as a result of granulomatous myocarditis: case report on a patient with metastatic melanoma treated with dabrafenib and trametinib.

Authors:  J K Winkler; K Buder-Bakhaya; E Ellert; E Herpel; U M Martens; A Enk; J C Hassel
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-08-02       Impact factor: 6.166

2.  Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib.

Authors:  Yanina J Jansen; Peter Janssens; Anne Hoorens; Max S Schreuer; Teofila Seremet; Sofie Wilgenhof; Bart Neyns
Journal:  Melanoma Res       Date:  2015-12       Impact factor: 3.599

3.  Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma.

Authors:  June J Park; Elena B Hawryluk; Steven R Tahan; Keith Flaherty; Caroline C Kim
Journal:  JAMA Dermatol       Date:  2014-03       Impact factor: 10.282

4.  Induced sarcoid-like reactions in patients with metastatic melanoma treated with dabrafenib and trametinib: a monocentric retrospective study.

Authors:  Sandra Huynh; Coralie Lheure; Nathalie Franck; Gabrielle Goldman-Lévy; Selim Aractingi; Nicolas Dupin; Nora Kramkimel; Sarah Guégan
Journal:  Melanoma Res       Date:  2020-06       Impact factor: 3.599

5.  BRAF Inhibitor-Associated Granulomatous Dermatitis: A Report of 3 Cases.

Authors:  Eugene Liat Hui Ong; Rishika Sinha; Shilan Jmor; Louise Fearfield
Journal:  Am J Dermatopathol       Date:  2019-03       Impact factor: 1.533

Review 6.  Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors.

Authors:  Ioannis Gkiozos; Alexandra Kopitopoulou; Alexandros Kalkanis; Ioannis N Vamvakaris; Marc A Judson; Konstantinos N Syrigos
Journal:  J Thorac Oncol       Date:  2018-05-12       Impact factor: 15.609

Review 7.  Your patient with melanoma: staging, prognosis, and treatment.

Authors:  Krista M Rubin; Donald P Lawrence
Journal:  Oncology (Williston Park)       Date:  2009-07       Impact factor: 2.990

8.  Granulomatous Reactions from Tattoos Following BRAF Inhibitor Therapy.

Authors:  Gabrielle Giet; Eve Lebas; Andrée Rorive; Jorge E Arrese; Arjen F Nikkels
Journal:  Case Rep Dermatol       Date:  2019-04-17

Review 9.  Sarcoidosis and Cancer: A Complex Relationship.

Authors:  Thomas El Jammal; Michel Pavic; Mathieu Gerfaud-Valentin; Yvan Jamilloux; Pascal Sève
Journal:  Front Med (Lausanne)       Date:  2020-11-24

10.  Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient.

Authors:  Andrea Boutros; Chiara Schiavi; Federica Cecchi; Francesco Spagnolo; Antonio Guadagno; Enrica Teresa Tanda; Francesca Giusti; Giuseppe Murdaca; Paola Queirolo
Journal:  Front Immunol       Date:  2020-11-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.